Nonhuman Primate Models of Osteoporosis
This chapter reviews the use of the nonhuman primate (NHP) as an animal model for osteoporosis research. While the previous chapters have extensively covered the use of lower species, the use of a higher species such as the NHP is likely to be the ultimate, or in some cases, the only relevant species to study bone in osteoporosis research. NHPs are used extensively in osteoporosis research in the pharmaceutical industry to evaluate new drug targets and in this context have contributed much to our current understanding of the human disease. This chapter focuses on the use of the NHP in drug development, presenting practical information on model selection and current techniques used to derive the primary end points of interest. Most of the practices described are considered relevant even in a basic research laboratory setting and will hopefully prove useful to researchers outside the pharmaceutical industry.
KeywordsBone Mineral Density Bone Turnover Bone Mineral Content Bone Quality Bone Densitometry
The authors wish to thank the technical teams in the Imaging, Histomorphometry, Biomechanics, and Immunochemistry laboratories at Charles River that made this work possible, and to Dr Luc Chouinard and Nancy Doyle for critical review of the manuscript.
- 7.FDA. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. In: Products DoMaED, ed. Rockville: Food and Drug Administration; 1994.Google Scholar
- 8.CHMP. Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis. London: European Medicines Agency; 2006.Google Scholar
- 9.JMHW. Guideline concerning the clinical evaluation method for Anti-Osteoporosis agents, pharmaceutical examination No. 742. In: Management BoH, ed.: issued by the Prefecural Bureau Chief, Bureau of Health Management, Section of Examination and Control, Bureau of Drug Safety, Japanese Ministry of Health and Welfare, 1999.Google Scholar
- 12.Smith SY, Varela A. Effect of diet (phytoestrogens) on the ovariectomy response in the cynomolgus monkey model of osteoporosis. J Bone Miner Res 2009; 24 (Suppl 1), SU0404.Google Scholar
- 18.Burr D, Hirano T, Turner C, et al. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001;16(1):157-165.PubMedCrossRefGoogle Scholar
- 22.Smith SY, Jolette J, Turner CH. Skeletal health: primate model of postmenopausal. Am J Primatol. 2009;71:1-14.Google Scholar
- 23.Fox J, Miller MA, Newman MK, et al. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res. 2007;22(2):260-273.PubMedCrossRefGoogle Scholar
- 28.Burghardt A, Kazakia G, Ramachandran S, et al. Age and gender related differences in the geometric properties and biomechanical significance of intra-cortical porosity in the distal radius and tibia. J Bone Miner Res. 2009;25(5):983-993 (Accepted article online: December 14, 2009).Google Scholar
- 37.Cline J, Botts S, Lees C, et al. Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis). Am J Obstet Gynecol 2008;199:158.el-8.Google Scholar
- 39.Doyle N, Smith S, Veverka K. Male and female cynomolgus monkey models of osteoporosis: comparative in vivo data. J Bone Miner Res. 2008;23:S353.Google Scholar